{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:29:36Z","timestamp":1787232576053,"version":"build-2736575974"},"reference-count":46,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Alfasigma S.p.A.","award":["DRS24SR.A.n.157"],"award-info":[{"award-number":["DRS24SR.A.n.157"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,8,7]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Guidelines for early rheumatoid arthritis (RA) recommend starting methotrexate, with optional glucocorticoid (GC) bridging, followed by treat-to-target intensifications after at least 3 months (routine care). Given RA\u2019s heterogeneity, we evaluated a stratified treat-to-target approach (tailor-made approach) consisting of two modifications to routine care: first-line disease-modifying antirheumatic drug (DMARD) selection stratified by autoantibody status and rapid treatment intensifications guided by early treatment response (within 1 month).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, open-label randomised controlled trial included adults with DMARD-na\u00efve RA (2010 American College of Rheumatology\/European Alliance of Associations for Rheumatology (EULAR) criteria) who were randomly assigned (1:1) to the tailor-made approach or routine care. Both arms followed a treat-to-target strategy, intensifying every 3\u20134 months until Disease Activity Score (DAS) \u22642.4. The tailor-made approach started MTX in autoantibody-positive patients and hydroxychloroquine in autoantibody-negative patients, both with intramuscular GC bridging. Additional intensifications at months 1 and 4 were allowed when DAS &gt;2.4, 1\u2009month after DMARD initiation or intensification, enabling treatment escalation before the standard 3-month reassessment. Routine care started MTX with GC bridging regardless of autoantibody status and without extra intensifications. The two primary outcomes were targeted synthetic\/biologic (ts\/b)DMARD use at 10 months and mean DAS over time; superiority required both to favour the tailor-made approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 308 included patients were randomised(152 tailor-made; 156 routine care). At 10 months, ts\/bDMARD use was 21% in the tailor-made approach vs 17% in routine care (one-sided p=0.20). Mean DAS trajectories were similar (p=0.57). No differences were observed in mean patient-reported outcome measure trajectories or adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Modifying the standard treat-to-target strategy, by stratifying the initial DMARD according to autoantibody status combined with rapidly intensifying therapy based on early treatment response, did not result in superior clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN16170070\">ISRCTN16170070<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-007217","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:05:16Z","timestamp":1787231116000},"page":"e007217","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management\u2014a multicentre, randomised, open-label trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"isrctn16170070","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn16170070","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn16170070","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-2182","authenticated-orcid":false,"given":"Agnes E M","family":"Looijen","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9487-6098","authenticated-orcid":false,"given":"Hamit Harun","family":"Dag","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-7922","authenticated-orcid":false,"given":"Judith W","family":"Heutz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-7407","authenticated-orcid":false,"given":"Floris A","family":"van Gaalen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam C","family":"Hegeman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H","family":"van der Kaap","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Admiraal De Ruyter Hospital, Goes, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy-Anne","family":"Korswagen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos C","family":"Padmos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, IJsselland Hospital, Capelle aan den IJssel, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Riyazi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Haga Hospital, Den Haag, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Tchetverikov","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josien J","family":"Veris-van Dieren","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Reumazorg ZWN, Roosendaal, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald E","family":"Vonkeman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, The Netherlands"},{"name":"Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Willemze","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-1437","authenticated-orcid":false,"given":"Annette H M","family":"van der Helm-van Mil","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-6222","authenticated-orcid":false,"given":"Pascal H P","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082006051235000_12.3.e007217.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026082006051235000_12.3.e007217.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2026082006051235000_12.3.e007217.3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","volume":"85","author":"Smolen","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026082006051235000_12.3.e007217.4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001653","article-title":"Possibilities for personalised medicine in rheumatoid arthritis: hype or hope","volume":"7","author":"Heutz","year":"2021","journal-title":"RMD Open"},{"key":"2026082006051235000_12.3.e007217.5","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026082006051235000_12.3.e007217.6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2103726"},{"key":"2026082006051235000_12.3.e007217.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204788"},{"key":"2026082006051235000_12.3.e007217.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205489"},{"key":"2026082006051235000_12.3.e007217.9","doi-asserted-by":"crossref","unstructured":"Verschueren P , De Cock D , Corluy L , et al . Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther 2015;17. doi:10.1186\/s13075-015-0611-8","DOI":"10.1186\/s13075-015-0611-8"},{"key":"2026082006051235000_12.3.e007217.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003296","article-title":"Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands","volume":"17","author":"Matthijssen","year":"2020","journal-title":"PLoS Med"},{"key":"2026082006051235000_12.3.e007217.11","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/rheumatology\/keab631","article-title":"The likelihood of attaining and maintaining DMARD-free remission for various (rheumatoid) arthritis phenotypes","volume":"61","author":"Luurssen-Masurel","year":"2022","journal-title":"Rheumatology"},{"key":"2026082006051235000_12.3.e007217.12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/00045632241285843","article-title":"Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: a comprehensive review","volume":"62","author":"Sahin","year":"2025","journal-title":"Ann Clin Biochem"},{"key":"2026082006051235000_12.3.e007217.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195550","article-title":"Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study","volume":"13","author":"Choi","year":"2018","journal-title":"PLoS ONE"},{"key":"2026082006051235000_12.3.e007217.14","article-title":"Towards stratified treatment of rheumatoid arthritis","volume":"15","author":"Luurssen-Masurel","year":"2020","journal-title":"Int J Clin Rheumatol"},{"key":"2026082006051235000_12.3.e007217.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137943"},{"key":"2026082006051235000_12.3.e007217.16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"The Lancet"},{"key":"2026082006051235000_12.3.e007217.17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/acr.23294","article-title":"Cluster\u2010Randomized Trial of a Behavioral Intervention to Incorporate a Treat\u2010to\u2010Target Approach to Care of US Patients With Rheumatoid Arthritis","volume":"70","author":"Harrold","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082006051235000_12.3.e007217.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202152"},{"key":"2026082006051235000_12.3.e007217.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"2026082006051235000_12.3.e007217.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken204"},{"key":"2026082006051235000_12.3.e007217.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-108887","article-title":"PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach","volume":"15","author":"Dag","year":"2025","journal-title":"BMJ Open"},{"key":"2026082006051235000_12.3.e007217.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2026082006051235000_12.3.e007217.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.001"},{"key":"2026082006051235000_12.3.e007217.24","unstructured":"Dijkmans BA , Jacobs JW , Jansen TL , et al . Richtlijnen medicijnen: methotrexaat. 2011. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/09\/NVR-Medicijnen-MTX-richtlijn-2009-update-2011.pdf"},{"key":"2026082006051235000_12.3.e007217.25","unstructured":"Huizinga TWJ , Nurmohamed MT . Standpunt van de Nederlandse Vereniging voor Reumatologie inzake JAK-remmers. 2018. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/10\/Jak-remmers-sept-2018.pdf"},{"key":"2026082006051235000_12.3.e007217.26","unstructured":"Baeten DL , Bijl M , Bijlsma JW , et al . Verantwoord gebruik van biologicals, 2011. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/09\/NVR-Medicijnen-richtlijn-verantwoord-gebruik-van-biologicals-januari-2011.pdf"},{"key":"2026082006051235000_12.3.e007217.27","unstructured":"Speyer I . Richtlijnen medicijnen: sulfasalazine. 2002. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/09\/NVR-Medicijnen-richtlijn-Sulfasalazine-2002.pdf"},{"key":"2026082006051235000_12.3.e007217.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"2026082006051235000_12.3.e007217.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"},{"key":"2026082006051235000_12.3.e007217.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211375"},{"key":"2026082006051235000_12.3.e007217.31","first-page":"S22","article-title":"Disease activity measures for rheumatoid arthritis","volume":"25","author":"Dougados","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2026082006051235000_12.3.e007217.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2026082006051235000_12.3.e007217.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.059451"},{"key":"2026082006051235000_12.3.e007217.34","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026082006051235000_12.3.e007217.35","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2026082006051235000_12.3.e007217.36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch Tariff for the Five-Level Version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value in Health"},{"key":"2026082006051235000_12.3.e007217.37","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2026082006051235000_12.3.e007217.38","unstructured":"StataCorp . Stata statistical software: release 19. College Station, TX: StataCorp LLC,"},{"key":"2026082006051235000_12.3.e007217.39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/annrheumdis-2019-215304","article-title":"Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials","volume":"78","author":"Verhoeven","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026082006051235000_12.3.e007217.40","doi-asserted-by":"crossref","first-page":"152748","DOI":"10.1016\/j.semarthrit.2025.152748","article-title":"A comparison of short-term efficacy and toxicity of 2 glucocorticoid bridging strategies in 2 clinical trials in early rheumatoid and undifferentiated arthritis","volume":"73","author":"van der Pol","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026082006051235000_12.3.e007217.41","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/rheumatology\/keac582","article-title":"Favourable effect of a \u201csecond hit\u201d after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial","volume":"62","author":"Hartman","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026082006051235000_12.3.e007217.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764"},{"key":"2026082006051235000_12.3.e007217.43","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026082006051235000_12.3.e007217.44","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110392"},{"key":"2026082006051235000_12.3.e007217.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2003.09.004"},{"key":"2026082006051235000_12.3.e007217.46","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-007217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:05:21Z","timestamp":1787231121000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-007217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-007217"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-007217","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}